Immunogenicity and safety of trivalent inactivated influenza vaccine

A randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country

Joon-Young Song, Hee-Jin Cheong, Heung Jeong Woo, Seong Heon Wie, Jin Soo Lee, Moon Hyun Chung, Yang Ree Kim, Sook In Jung, Kyung Hwa Park, Tae Hyong Kim, Soo Taek Uh, Woo Joo Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Influenza vaccines are the primary method for controlling influenza and its complications. This study was conducted as a phase 3, randomized, double-blind, controlled, multicenter trial at seven university hospitals to evaluate the immunogenicity and safety of an inactivated, split, trivalent influenza vaccine (GC501, Green Cross Corporation, Yongin, Korea), which was newly manufactured in Korea in 2008. Between September 21 and 26, a total of 329 healthy subjects were recruited for the immunogenicity analysis, while 976 subjects were enrolled for the safety analysis. The GC501 vaccine met both FDA and EMEA criteria with ≥ 80% of subjects achieving post-vaccination titers ≥ 40 for all three subtypes, even in the elderly. The vaccine was well tolerated with only mild systemic and local adverse events. In summary, GC501 showed excellent immunogenicity and a good safety profile in both young adults and the elderly. The licensure of GC501 might be an important basis in preparation for the future influenza pandemic.

Original languageEnglish
Pages (from-to)191-195
Number of pages5
JournalJournal of Korean Medical Science
Volume26
Issue number2
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Phase III Clinical Trials
Inactivated Vaccines
Influenza Vaccines
Vaccines
Korea
Safety
Human Influenza
Pandemics
Licensure
Multicenter Studies
Young Adult
Healthy Volunteers
Vaccination

Keywords

  • Human
  • Inactivated
  • Influenza
  • Influenza Vaccines
  • Vaccines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunogenicity and safety of trivalent inactivated influenza vaccine : A randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. / Song, Joon-Young; Cheong, Hee-Jin; Woo, Heung Jeong; Wie, Seong Heon; Lee, Jin Soo; Chung, Moon Hyun; Kim, Yang Ree; Jung, Sook In; Park, Kyung Hwa; Kim, Tae Hyong; Uh, Soo Taek; Kim, Woo Joo.

In: Journal of Korean Medical Science, Vol. 26, No. 2, 01.02.2011, p. 191-195.

Research output: Contribution to journalArticle

Song, Joon-Young ; Cheong, Hee-Jin ; Woo, Heung Jeong ; Wie, Seong Heon ; Lee, Jin Soo ; Chung, Moon Hyun ; Kim, Yang Ree ; Jung, Sook In ; Park, Kyung Hwa ; Kim, Tae Hyong ; Uh, Soo Taek ; Kim, Woo Joo. / Immunogenicity and safety of trivalent inactivated influenza vaccine : A randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. In: Journal of Korean Medical Science. 2011 ; Vol. 26, No. 2. pp. 191-195.
@article{14df327b56ea481abf4fa4e14c57f897,
title = "Immunogenicity and safety of trivalent inactivated influenza vaccine: A randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country",
abstract = "Influenza vaccines are the primary method for controlling influenza and its complications. This study was conducted as a phase 3, randomized, double-blind, controlled, multicenter trial at seven university hospitals to evaluate the immunogenicity and safety of an inactivated, split, trivalent influenza vaccine (GC501, Green Cross Corporation, Yongin, Korea), which was newly manufactured in Korea in 2008. Between September 21 and 26, a total of 329 healthy subjects were recruited for the immunogenicity analysis, while 976 subjects were enrolled for the safety analysis. The GC501 vaccine met both FDA and EMEA criteria with ≥ 80{\%} of subjects achieving post-vaccination titers ≥ 40 for all three subtypes, even in the elderly. The vaccine was well tolerated with only mild systemic and local adverse events. In summary, GC501 showed excellent immunogenicity and a good safety profile in both young adults and the elderly. The licensure of GC501 might be an important basis in preparation for the future influenza pandemic.",
keywords = "Human, Inactivated, Influenza, Influenza Vaccines, Vaccines",
author = "Joon-Young Song and Hee-Jin Cheong and Woo, {Heung Jeong} and Wie, {Seong Heon} and Lee, {Jin Soo} and Chung, {Moon Hyun} and Kim, {Yang Ree} and Jung, {Sook In} and Park, {Kyung Hwa} and Kim, {Tae Hyong} and Uh, {Soo Taek} and Kim, {Woo Joo}",
year = "2011",
month = "2",
day = "1",
doi = "10.3346/jkms.2011.26.2.191",
language = "English",
volume = "26",
pages = "191--195",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "2",

}

TY - JOUR

T1 - Immunogenicity and safety of trivalent inactivated influenza vaccine

T2 - A randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country

AU - Song, Joon-Young

AU - Cheong, Hee-Jin

AU - Woo, Heung Jeong

AU - Wie, Seong Heon

AU - Lee, Jin Soo

AU - Chung, Moon Hyun

AU - Kim, Yang Ree

AU - Jung, Sook In

AU - Park, Kyung Hwa

AU - Kim, Tae Hyong

AU - Uh, Soo Taek

AU - Kim, Woo Joo

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Influenza vaccines are the primary method for controlling influenza and its complications. This study was conducted as a phase 3, randomized, double-blind, controlled, multicenter trial at seven university hospitals to evaluate the immunogenicity and safety of an inactivated, split, trivalent influenza vaccine (GC501, Green Cross Corporation, Yongin, Korea), which was newly manufactured in Korea in 2008. Between September 21 and 26, a total of 329 healthy subjects were recruited for the immunogenicity analysis, while 976 subjects were enrolled for the safety analysis. The GC501 vaccine met both FDA and EMEA criteria with ≥ 80% of subjects achieving post-vaccination titers ≥ 40 for all three subtypes, even in the elderly. The vaccine was well tolerated with only mild systemic and local adverse events. In summary, GC501 showed excellent immunogenicity and a good safety profile in both young adults and the elderly. The licensure of GC501 might be an important basis in preparation for the future influenza pandemic.

AB - Influenza vaccines are the primary method for controlling influenza and its complications. This study was conducted as a phase 3, randomized, double-blind, controlled, multicenter trial at seven university hospitals to evaluate the immunogenicity and safety of an inactivated, split, trivalent influenza vaccine (GC501, Green Cross Corporation, Yongin, Korea), which was newly manufactured in Korea in 2008. Between September 21 and 26, a total of 329 healthy subjects were recruited for the immunogenicity analysis, while 976 subjects were enrolled for the safety analysis. The GC501 vaccine met both FDA and EMEA criteria with ≥ 80% of subjects achieving post-vaccination titers ≥ 40 for all three subtypes, even in the elderly. The vaccine was well tolerated with only mild systemic and local adverse events. In summary, GC501 showed excellent immunogenicity and a good safety profile in both young adults and the elderly. The licensure of GC501 might be an important basis in preparation for the future influenza pandemic.

KW - Human

KW - Inactivated

KW - Influenza

KW - Influenza Vaccines

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=79551679046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551679046&partnerID=8YFLogxK

U2 - 10.3346/jkms.2011.26.2.191

DO - 10.3346/jkms.2011.26.2.191

M3 - Article

VL - 26

SP - 191

EP - 195

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 2

ER -